APLM

Apollomics Inc. (APLM) | Rumor.io

Apollomics

APLM

Attention (50-day avg)0%

Attention rank (50-day avg)#3,081

Bullish sentiment (50-day avg)63%

Price to earnings ratio0

Market capitalization69.5M

Earnings per share-7.57

Dividend yield (TTM)—

Revenue (annual)8.5M

Net income (annual)-10.9M

Social

What share of all stock conversation is about APLM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 29

APLM has experienced a strong technical breakout above its SMA50, resulting in an 11% surge, with key catalysts including halt clearance and oversold rebound momentum in the biotech sector.
APLM is forming a multi-month volatility contraction after its significant move in September, indicating potential stability in the stock.
APLM has shown a notable pullback, with the stock caught at $21.07 and now trading at $22.78, representing a 9% gain.

Generated by AI

Sentiment

Of the messages about APLM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -65.22	86.85% +4.31
Bearish	—	—	100% +65.22	13.15% -4.31

Bullish· Oct 16

$APLM is heading for a strong close, with a 42% increase in value, driven by funding news and a reversal of wind-up plans.
Apollomics' recent leadership reset has set a clearer focus on high-value trials and partnerships, aligning the company toward sustainable biotech growth.
The company's biotech revival play is fueled by fresh funds, new leadership, and a sharpened pipeline, making it a potential rebound story for investors seeking early-stage biotech upside.

Bearish· Sep 17

The company's non-compliance with NASDAQ listing requirements has resulted in a trading halt, which may lead to delisting and a significant decrease in value.
The asset's recent pump and potential dump scenario, with a significant price increase in a short period, may indicate manipulation and a subsequent massive drop in value.
The T-12 halt and potential move to pink sheets may make it difficult for the company to recover, leading to a significant decrease in value, potentially below $1.

Generated by AI

Topics

Of the messages about APLM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	49.04%
Technical Analysis	—	—	100%	31.98%
Analysts	—	—	0%	7.89%
Controversies	—	—	0%	0.64%
Earnings	—	—	0%	0%
Macro	—	—	0%	10.45%

Announcements· Nov 16

Apollomics, Inc. (APLM) announced the first approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer in China.
The NMPA of China conditionally approved the commercialization of Vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).
Apollomics is in active discussion with the U.S. FDA regarding a New Drug Application (NDA) for Vebreltinib based on totality of clinical data from the global SPARTA trial and Avistone's KUNPENG trial in China.

Technical Analysis· Nov 18

$APLM has broken out and is showing strong momentum, with a 50% gain since its initial mention.
The asset is bouncing off its lower Bollinger Line and showing heavy volume, indicating a potential multi-day runner.
The 50ema is looking to cross over the 200ema on the 2min chart, which could be a key indicator of a potential breakout.

Generated by AI

Community

Of the messages about APLM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	91.3%	35.53%
Newcomers	—	—	8.7%	64.47%

Regulars· Sep 17

APLM is showing high relative strength and is forming a tight pennant after a strong move, with the stock consolidating near highs around 20.
The stock's high volume surge and RSI signaling bullish vibes suggest a breakout, with the chart looking electric and momentum strong.
APLM needs to stay above VWAP to continue its uptrend, and the stock is recommended to be kept on radar for potential opportunities.

Newcomers· Dec 29

The $APLM stock has experienced a strong technical breakout above the SMA50, resulting in an 11% surge, with key catalyst being the halt clearance and oversold rebound momentum in biotech.
$APLM has formed a multi-month volatility contraction after its huge move in September, indicating a potential calm before the next significant price movement.
The stock has seen significant price movements, with the stock price increasing from $21.07 to $22.78 and $23.26 in recent trading sessions, suggesting a strong trend in its favor.

Generated by AI

News

Apollomics Announces $10 Million Private Placement Transaction

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), fo

1mo agoYahoo Finance

Also Discussed

Investors talking about APLM also mention

#	Name	Attention
1	Naya Biosciences Inc.INVO	0%0
2	PaxMedica Inc.PXMD	0%0
3	noco-noco Inc.NCNC	0%0
4	SGD - Safe and Green Development Corporation	——
5	Cardio Diagnostics Holdings, Inc.CDIO	0%0
6	American BriVision (Holding) CorporationABVC	0%+0
7	Ambipar Emergency Response Inc.AMBI	0%new
8	LSB - LakeShore Biopharma Co., Ltd	——
9	Zura Bio LimitedZURA	0%new
10	Falcon's Beyond Global, Inc. Class A Common StockFBYD	0%new

Apollomics Inc.

Healthcare
Biotechnology

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options. Its lead programs include vebreltinib, an oral c-Met inhibitor being studied in solid tumors with MET dysregulation, and APL-102, an oral multi-kinase inhibitor in early-stage cancer development. Apollomics also evaluates therapies for difficult-to-treat cancers such as non-small cell lung cancer and acute myeloid leukemia. Based in Foster City, California, Apollomics operates as a specialized biotechnology company within the broader oncology drug-development market, where it contributes experimental therapies aimed at precision medicine and unmet medical needs.

Website

Location

989 East Hillsdale Blvd.

Foster City, CA, 94404

United States

Social

What share of all stock conversation is about APLM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 29

APLM has experienced a strong technical breakout above its SMA50, resulting in an 11% surge, with key catalysts including halt clearance and oversold rebound momentum in the biotech sector.
APLM is forming a multi-month volatility contraction after its significant move in September, indicating potential stability in the stock.
APLM has shown a notable pullback, with the stock caught at $21.07 and now trading at $22.78, representing a 9% gain.

Generated by AI

Sentiment

Of the messages about APLM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -65.22	86.85% +4.31
Bearish	—	—	100% +65.22	13.15% -4.31

Bullish· Oct 16

$APLM is heading for a strong close, with a 42% increase in value, driven by funding news and a reversal of wind-up plans.
Apollomics' recent leadership reset has set a clearer focus on high-value trials and partnerships, aligning the company toward sustainable biotech growth.
The company's biotech revival play is fueled by fresh funds, new leadership, and a sharpened pipeline, making it a potential rebound story for investors seeking early-stage biotech upside.

Bearish· Sep 17

The company's non-compliance with NASDAQ listing requirements has resulted in a trading halt, which may lead to delisting and a significant decrease in value.
The asset's recent pump and potential dump scenario, with a significant price increase in a short period, may indicate manipulation and a subsequent massive drop in value.
The T-12 halt and potential move to pink sheets may make it difficult for the company to recover, leading to a significant decrease in value, potentially below $1.

Generated by AI

Topics

Of the messages about APLM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	49.04%
Technical Analysis	—	—	100%	31.98%
Analysts	—	—	0%	7.89%
Controversies	—	—	0%	0.64%
Earnings	—	—	0%	0%
Macro	—	—	0%	10.45%

Announcements· Nov 16

Apollomics, Inc. (APLM) announced the first approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer in China.
The NMPA of China conditionally approved the commercialization of Vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).
Apollomics is in active discussion with the U.S. FDA regarding a New Drug Application (NDA) for Vebreltinib based on totality of clinical data from the global SPARTA trial and Avistone's KUNPENG trial in China.

Technical Analysis· Nov 18

$APLM has broken out and is showing strong momentum, with a 50% gain since its initial mention.
The asset is bouncing off its lower Bollinger Line and showing heavy volume, indicating a potential multi-day runner.
The 50ema is looking to cross over the 200ema on the 2min chart, which could be a key indicator of a potential breakout.

Generated by AI

Community

Of the messages about APLM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	91.3%	35.53%
Newcomers	—	—	8.7%	64.47%

Regulars· Sep 17

APLM is showing high relative strength and is forming a tight pennant after a strong move, with the stock consolidating near highs around 20.
The stock's high volume surge and RSI signaling bullish vibes suggest a breakout, with the chart looking electric and momentum strong.
APLM needs to stay above VWAP to continue its uptrend, and the stock is recommended to be kept on radar for potential opportunities.

Newcomers· Dec 29

The $APLM stock has experienced a strong technical breakout above the SMA50, resulting in an 11% surge, with key catalyst being the halt clearance and oversold rebound momentum in biotech.
$APLM has formed a multi-month volatility contraction after its huge move in September, indicating a potential calm before the next significant price movement.
The stock has seen significant price movements, with the stock price increasing from $21.07 to $22.78 and $23.26 in recent trading sessions, suggesting a strong trend in its favor.

Generated by AI

Apollomics

Social

Dec 29

Bullish· Oct 16

Bearish· Sep 17

Announcements· Nov 16

Technical Analysis· Nov 18

Regulars· Sep 17

Newcomers· Dec 29

Monday’s insider activity: Major buys at Cardinal, Apollomics

Apollomics CFO Peter Lin buys $400,005 in shares

Apollomics COO Chen Yi-Kuei buys $300,000 in shares

Apollomics CEO Chen Hung-Wen acquires $7.55 million in stock

Apollomics raises $10 million in private placement

Apollomics Announces $10 Million Private Placement Transaction

Also Discussed

Apollomics Inc.

Company Information

Location

Monday’s insider activity: Major buys at Cardinal, Apollomics

Apollomics CFO Peter Lin buys $400,005 in shares

Apollomics COO Chen Yi-Kuei buys $300,000 in shares

Apollomics CEO Chen Hung-Wen acquires $7.55 million in stock

Apollomics raises $10 million in private placement

Apollomics Announces $10 Million Private Placement Transaction

Also Discussed

Social

Dec 29

Bullish· Oct 16

Bearish· Sep 17

Announcements· Nov 16

Technical Analysis· Nov 18

Regulars· Sep 17

Newcomers· Dec 29